Company intelligence / Profile preview

Anbison Lab

San Diego, California, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Anbison Lab is a biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) and multi-specific antibodies for oncology. The company utilizes its proprietary AnbiADC platform for site-specific conjugation and its dual-payload technology to create more stable and potent therapies. Its lead program, ANB101, is a HER2-targeting ADC currently in early clinical development, while its pipeline includes innovative bispecific ADCs designed to overcome traditional resistance mechanisms in solid tumors.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibodyBispecific monoclonal antibodySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Anbison Lab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anbison Lab.

Explore the full profile